Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · breast-umap@18

TCGA-AC-A2FF-01A-11R-A17B-07

— · A

3dece7fe-8242-59ea-985f-fd87d84e0e8b

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
A
subtype
A
overall_survival_months
92

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • UV_RESPONSE_DN+0.460
  • ALLOGRAFT_REJECTION+0.370
  • HEDGEHOG_SIGNALING+0.350
  • KRAS_SIGNALING_UP+0.320
  • IL6_JAK_STAT3_SIGNALING+0.310
  • COAGULATION+0.250
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
  • INFLAMMATORY_RESPONSE+0.220
  • IL2_STAT5_SIGNALING+0.210
  • ANGIOGENESIS+0.200

Top 10 suppressed

  • MYC_TARGETS_V2-0.570
  • E2F_TARGETS-0.480
  • G2M_CHECKPOINT-0.430
  • DNA_REPAIR-0.410
  • MTORC1_SIGNALING-0.410
  • MYC_TARGETS_V1-0.410
  • GLYCOLYSIS-0.400
  • OXIDATIVE_PHOSPHORYLATION-0.390
  • UV_RESPONSE_UP-0.390
  • UNFOLDED_PROTEIN_RESPONSE-0.260

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

10 twins match this tumor's tissue · 0 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
120040019.LumA
breast-umap@18
—A0.922
220020074.LumA
breast-umap@18
—A0.915
3895018d4-b355-4339-8c60-186478ae6551
colon-landscapes@1
——0.893
4TCGA-AC-A6IV-01A-12R-A33J-07
breast-umap@18
—A0.890
5TCGA-CN-5358-01A-01R-1514-07
head-neck@1
——0.885
6TCGA-G2-A2EC-01A-11R-A180-07
bladder-landscape@3
——0.883
7SRR8518299
breast-umap@18
—A0.882
8TCGA-CR-7393-01A-11R-2016-07
head-neck@1
——0.881
9TCGA-98-A53C-01A-11R-A262-07
lung-landscapes@6
—cohortMD20.880
10SRR8518405
breast-umap@18
—A0.879

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 26 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
UV_RESPONSE_DN0.460Inavolisib— uncovered
ALLOGRAFT_REJECTION0.370Idelalisib— uncovered
HEDGEHOG_SIGNALING0.350Inavolisib— uncovered
KRAS_SIGNALING_UP0.320Inavolisib— uncovered
IL6_JAK_STAT3_SIGNALING0.310Inavolisib— uncovered
COAGULATION0.250Binimetinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.240Inavolisib— uncovered
INFLAMMATORY_RESPONSE0.220Idelalisib— uncovered
IL2_STAT5_SIGNALING0.210Idelalisib— uncovered
ANGIOGENESIS0.200Remibrutinib— uncovered
MYOGENESIS0.200Inavolisib— uncovered
TGF_BETA_SIGNALING0.200Inavolisib— uncovered
BILE_ACID_METABOLISM0.190Inavolisib— uncovered
COMPLEMENT0.180Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.150Inavolisib— uncovered
INTERFERON_GAMMA_RESPONSE0.140Idelalisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.140Inavolisib— uncovered
PANCREAS_BETA_CELLS0.090Cobimetinib— uncovered
APICAL_JUNCTION0.080Inavolisib— uncovered
KRAS_SIGNALING_DN0.080Remibrutinib— uncovered